Get the Stockscreener App
33.79
8.63%
-3.19
After Hours:
33.79
Enovis Corp stock is traded at $33.79, with a volume of 1.33M.
It is down -8.63% in the last 24 hours and down -10.75% over the past month.
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.
See More
Previous Close:
$36.98
Open:
$35.25
24h Volume:
1.33M
Relative Volume:
1.51
Market Cap:
$1.92B
Revenue:
$2.00B
Net Income/Loss:
$-119.19M
P/E Ratio:
-15.43
EPS:
-2.19
Net Cash Flow:
$-61.88M
1W Performance:
-13.09%
1M Performance:
-10.75%
6M Performance:
-15.44%
1Y Performance:
-43.06%
1-Day Range:
$33.73
$35.44
1-Week Range:
$33.73
$38.56
52-Week Range:
$33.73
$62.79
Enovis Corp Stock (ENOV) Company Profile
Name
Enovis Corp
Sector
Industry
Phone
(302) 252-9160
Address
2711 CENTERVILLE ROAD, WILMINGTON
Compare ENOV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENOV
Enovis Corp
|
33.79 | 1.92B | 2.00B | -119.19M | -61.88M | -2.19 |
|
ABT
Abbott Laboratories
|
131.63 | 228.29B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
98.50 | 145.69B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
368.15 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
87.89 | 112.70B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.98 | 42.75B | 5.72B | 4.17B | 259.90M | 6.97 |
Enovis Corp Stock (ENOV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-03-24 | Initiated | JMP Securities | Mkt Outperform |
| Jun-13-24 | Initiated | JP Morgan | Neutral |
| Feb-13-24 | Initiated | Stephens | Overweight |
| Jan-22-24 | Initiated | UBS | Buy |
| Jan-03-24 | Initiated | William Blair | Outperform |
| Dec-15-23 | Reiterated | Needham | Buy |
| Oct-20-23 | Initiated | ROTH MKM | Buy |
| Jun-26-23 | Initiated | Needham | Buy |
| May-12-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Oct-11-22 | Initiated | Goldman | Buy |
| Sep-12-22 | Initiated | Canaccord Genuity | Buy |
| Sep-12-22 | Initiated | Evercore ISI | Outperform |
| Jun-28-22 | Initiated | Argus | Hold |
| Jun-27-22 | Resumed | Loop Capital | Buy |
| Jun-16-22 | Initiated | Wells Fargo | Equal Weight |
View All
Enovis Corp Stock (ENOV) Latest News
Canaccord maintains Buy rating and $75 target for Enovis stock - Investing.com Australia
Enovis Receives Buy Rating Amidst Strategic Leadership Change and Strong Financial Projections - TipRanks
Enovis’s Promising Future: Buy Rating Backed by Strategic Leadership and Positive Financial Outlook - TipRanks
Enovis names Damien McDonald as new CEO starting May 12 By Investing.com - Investing.com Canada
Enovis Names Damien McDonald as New CEO to Drive Next Growth Chapter - MSN
Analysts Have Conflicting Sentiments on These Industrial Goods Companies: Enovis (ENOV) and Auckland International Airport Limited (OtherACKDF) - The Globe and Mail
Enovis names Damien McDonald as CEO, succeeding Matt Trerotola - TipRanks
Strategic Leadership and Financial Stability Drive Buy Rating for Enovis - TipRanks
Enovis (ENOV) Appoints New CEO and Confirms Revenue Forecast - GuruFocus
Enovis Corporation Reiterats Earnings Guidance for the First Quarter of 2025 - MarketScreener
Former LivaNova CEO to take corner office at Enovis - MassDevice
Enovis names McDonald as CEO - MSN
Enovis Names Damien McDonald as Chief Executive; Reaffirms Q1 Revenue Guidance - MarketScreener
Enovis names Damien McDonald as new CEO starting May 12 - Investing.com India
Enovis Appoints Damien McDonald as New CEO - TipRanks
Enovis Announces Appointment of Damien McDonald as Chief Executive Officer - The Manila Times
Enovis Announces Appointment Of Damien Mcdonald As Chief Executive Officer - MarketScreener
Medical Device Expert Takes Helm at Enovis: Former LivaNova CEO to Drive Growth - Stock Titan
Enovis Corporation (NYSE:ENOV) Looks Inexpensive But Perhaps Not Attractive Enough - simplywall.st
Enovis Showcases Innovative Foot and Ankle Solutions at ACFAS Conference - MSN
Enovis™ to Exhibit Extensive Range of Foot & Ankle Solutions at ACFAS 2025 - GlobeNewswire
Enovis, Foundation Surgical and J&J MedTech Named Winners of OMTEC® Awards, Honoring Excellence in Orthopedic Innovation - Ortho Spine News
Revolutionary Bunion Surgery System Leads Enovis's Major Product Launch at ACFAS 2025 - Stock Titan
Enovis : trade; Publishes 2024 Corporate Social Responsibility Report -March 24, 2025 at 04:41 pm EDT - MarketScreener
Enovis Corp (ENOV) Stock Price Up 1.77% on Mar 19 - GuruFocus.com
Enovis Plans Leadership Change - The Healthcare Technology Report.
Enovis CEO Matthew Trerotola Announces Retirement Plan - TipRanks
Positive Outlook for Enovis: Strong Market Position and Strategic Growth Initiatives - TipRanks
Diabetic Footwear Market Demand : Identifying Key Growth Opportunities By 2032 | Enovis companies, Pilgrim - EIN News
Enovis Corporation Announces Participation in Upcoming Investor Conferences - MSN
Enovis Positioned for Growth: Buy Rating Highlights Strategic Execution and Undervaluation - TipRanks
Enovis to Participate in Upcoming Investor Conferences - The Manila Times
Enovis Leadership Reveals Investor Conference Schedule: Key Dates for Healthcare Investors - StockTitan
Enovis Hits Another 52-Week Low. Here’s Why It’s A Contrarian Buy. - Barchart
Enovis Hits Another 52-Week Low. Here’s Why It’s a Contrarian Buy. - TradingView
Enovis : rsquo; Louie Vogt on driving recon growth past $1B with M&A, knee breakthroughs, and foot and ankle expansion - Marketscreener.com
Enovis Corporation Reports Strong Growth Amid Challenges - MSN
William Blair Issues Optimistic Outlook for Enovis Earnings - MarketBeat
Enovis (NYSE:ENOV) Issues FY 2025 Earnings Guidance - MarketBeat
Enovis (ENOV) Q4 Earnings and Revenues Surpass Estimates - MSN
Enovis Positioned for Growth: Buy Rating Backed by Strong Sales, Product Launches, and Attractive Valuation - TipRanks
Enovis (NYSE:ENOV) Reaches New 1-Year Low on Analyst Downgrade - MarketBeat
Enovis Reports Strong 2024 Sales Growth Despite Goodwill Impairment Charge - MSN
Needham & Company LLC Has Lowered Expectations for Enovis (NYSE:ENOV) Stock Price - MarketBeat
Enovis Continues To Languish Despite Decent Financial Results (NYSE:ENOV) - Seeking Alpha
Decoding Enovis Corp (ENOV): A Strategic SWOT Insight - GuruFocus.com
Diabetic Footwear Market Future Business Opportunities 2025-2032 | Enovis companies, Pilgrim Shoes, Drew Shoe - EIN News
Enovis (NYSE:ENOV) Issues Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Enovis Corporation (NYSE:ENOV) Q4 2024 Earnings Call Transcript - Insider Monkey
Enovis Corp Stock (ENOV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.71%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):